Home/ Stocks/ EDIT

Editas Medicine, Inc. Common Stock

EDIT XNAS

$3.11 +0.07 (+2.29%) ▲ 15-min delayed

Open

$3.03

High

$3.23

Low

$3.03

Volume

1.12M

Market Cap

$304.49M

About Editas Medicine, Inc. Common Stock

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 87 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$2.83M	$-24,982,000	$-0.26
FY 2025	$40.52M	$-160,060,000	$-1.80
Q3 2025	$7.54M	$-25,117,000	$-0.28
Q2 2025	$3.58M	$-53,235,000	$-0.63

Related Market News

No specific coverage for EDIT yet. Check out our latest market news or earnings calendar.

Get EDIT Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Editas Medicine, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.